病例分享:肝移植术后严重贫血一例

2018-01-04 佚名 爱肝一生微课堂

王先生,50岁,汉族,肝移植术后1月余,乏力、头昏1周,入院治疗。

病例摘要

一般情况

王先生,50岁,汉族,肝移植术后1月余,乏力、头昏1周,入院治疗。

有乙肝家族史,其母亲及1弟均为“慢性乙型肝炎”,与1990年“慢乙肝”,2005年“乙肝肝硬化并上消化道出血” 行内镜下食管曲张静脉套扎术;2010-12-27在我院行原位肝移植术;饮酒史15年,酒精100g/日,2008年戒酒, 吸烟史15年,平均每日约2-3支。

移植前疾病 :原发性肝癌,乙型肝炎肝硬化失代偿期 ;行经典原位肝移植术,围手术期恢复顺利;

病肝病理 :

1.肝细胞癌,高分化;切缘未见瘤组织;

2.乙型肝炎肝硬化

供肝病理:组织汇管区及小叶内结构正常,为正常肝组织 ;

移植后情况:无不适,肝功正常 ,1月后 乏力,头晕 无发热、咳嗽、呕吐、腹泻等表现,尿便正常。

特殊用药

抗排异治疗方案:

他克莫司胶囊 3mg/12H(FK506浓度:8.6-11ng/ml)

吗替麦考酚钠肠溶片 540mg/日 (严重呕吐),  醋酸泼尼松龙片 10mg/日

预防乙肝复发治疗方案:恩替卡韦片 0.5mg,1/日 ,乙型肝炎人免疫球蛋白 400单位/周

查体:T:36.5℃,P:75次/分,R:20次/分,BP:139/81mmHg ;

神志清,精神可,营养中等 ;皮肤、巩膜无黄染 ;睑结膜苍白,口唇苍白 ;

全身浅表淋巴结无肿大 、心肺无异常 、腹部可见正中“人”字型切口疤痕,全腹软,无压痛、反跳痛,肝、脾肋下未及,移动性浊音阴性,肠鸣音无亢进 、甲床稍苍白,双下肢无水肿,扑翼样震颤阴性。

常规检查:

血常规:WBC 1.05×109/L、0.60、RBC 2.02×1012/L、HCT 17.4%、HGB 59g/L、PLT 41×109/L;

肝功、肾功、血糖等生化指标无异常 ;凝血正常 ;FK506 8.6ng/ml

抗CMV IgM(-)、抗EBV IgM (-);肝脏超声、肝脏血管超声无异常。

-------------------------

病例特点

中年男性,肝移植术后1月;

主要表现

乏力、头昏;主要阳性体征:贫血貌(睑结膜、口唇苍白);

主要的异常结果

血常规:WBC 1.05×109/L、RBC 2.02×1012/L、HGB 59g/L、PLT 41×109/L (三系减少)

移植术后(2010-12-20)血常规

WBC 3.78×109/L、RBC 4.22×1012/L、HGB 105g/L、PLT 21×109/L (以血红蛋白明显下降为主 )

初步诊断

肝移植术后、贫血(重度)。

病因不同,血容量下降速度不同,临床表现不同,我们分析导致贫血的三大病因,生成减少性贫血,溶血性贫血,失血性贫血。

该患者无咯血、呕血、便血等出血表现排除失血性贫血,同时该患者胆红素水平正常,无发热、黄疸、血红蛋白尿等溶血现象,暂时不考虑溶血性贫血。

病因考虑为生成减少性贫血(包括:营养性贫血、再生障碍性贫血 、纯红细胞再生障碍性贫血 、造血恶性克隆病 、先天性红系异常 )。



进一步检查:复查血常规WBC 2.71×109/L、RBC 2.72×1012/L、HGB 60g/L、MCV  93.6、PLT 33×109/L (正常细胞性贫血);

网织红细胞绝对值0.004,网织红细胞百分比0.2%(提示红细胞生成不好,结果正常细胞性贫血的常见原因考虑骨髓造血功能受抑制可能性大),该患者术后营养较差,服用麦考芬滞出现了一个严重的呕吐,同时不除外营养性贫血,但更换药物改善营养后血色素未有明显好转。

同时血清铁23.2umol/l、转铁蛋白1.5g/l, 排除缺铁性贫血(小细胞低色素)。在病因上我们高度怀疑骨髓功能障碍,进行了骨髓穿刺术等待结果。



生成减少性贫血原因?

骨髓穿刺结果:骨髓增生活跃,粒系明显增生(基本排除了再障性贫血),红系增生受抑,全片可见巨核细胞171个,血小板散在分布。片中可多见一类大细胞,不除外转移癌细胞。

患者术前为原发性肝癌。

通过骨髓增生活跃,粒系明显增生,基本排除了再障性贫血,红系增生受抑考虑纯红细胞再生障碍性贫血,但报告又提示不除外转移癌细胞,结合患者术前为原发性肝癌,是否存在肝癌复发转移导致骨髓受侵犯的可能(肿瘤相关贫血)。后续进一步检查PET-CT结果提示患者无全身肿瘤转移,排除了转移癌,同时进行了二次骨髓穿刺复查,期间同时间断输注红细胞对症治疗。

二次骨髓穿刺结果:纯红细胞再生障碍性贫血?

再次行骨髓穿刺术,送外院阅片,结果提示骨髓增生活跃,粒系明显增生,红系增生受抑,见大核、深染原红细胞,巨系正常。

301医院血液科会诊后考虑为“纯红细胞再生障碍性贫血”。

-------------------------

最后诊断

纯红细胞再生障碍性贫血。

诊断依据

临床表现:头晕、乏力、失眠等诸多阴性症状;

实验室检查:外周血红细胞、血红蛋白、网织红细胞显着减少,白细胞和血小板无下降;

骨髓穿刺:骨髓中红细胞系统极度减少,而粒细胞系统增生正常。同时排除了其他原因的贫血和发热。

纯红细胞再生障碍性贫血治疗原则

1. 避免接触对骨髓造血可能的有毒性物质

2. 促进骨髓造血功能

3.支持疗法:输血

4.治疗原发病

该患者为肝移植术后长期服用他克莫司,不排除抗排异反应他克莫司抑制骨髓造血功能可能,予以环孢素替代治疗(环孢素血药浓度维持在200ng/ml左右),同时间断输注红细胞支持治疗。

2011年3月25复查血常规:WBC 2.05×109/L、N:0.76、HGB 43g/L、PLT 39×109/L;

肝功、肾功、电解质基本正常 ;

血红蛋白水平无好转,治疗上加用十一酸睾铜胶丸刺激骨髓造血 。

血红蛋白仍未好转,导致纯红再障真正原因是?

2011年3月29日复查血常规:WBC 1.95×109/L、N、0.69、HGB 44g/L、PLT    36×109/L ,血红蛋白仍没有好转,前期治疗已经停用他克莫司并换用了环孢素,并予以十一酸睾铜胶丸刺激骨髓造血但疗效欠佳。

肝移植术后导致纯红再障的真正原因是什么呢?

免疫力差导致的病毒感染,特别是微小被病毒B19是肝移植术后出现纯红再障的易发因素,该患者为移植术后2个月极易发生感染,因此存在因免疫力差导致微小被病毒B19感染的可能。

4月初化验结果回报:微小病毒B19 IgM 阳性 ,为排除误差进一步301医院血液科复查微小病毒B19 IgM也是阳性 。最后根据以上推断明确了诊断。

1.微小病毒B19感染致纯红细胞再生障碍性贫血(重度)

2.肝移植术后状态

针对病因给予大剂量丙种球蛋白0.4g/kg/d×5d 治疗。

随访

2011年4月29日

血常规:WBC 3.74×109/L、HGB 85g/L、PLT 42×109/L ;

2011年6月2日

血常规:WBC 3.21×109/L、HGB 120g/L、PLT  43×109/L 。

在未予输血的情况下,血红蛋白稳定。治疗后骨髓象恢复情况 ,复查骨髓穿刺结果:增生活跃,粒系、巨核系各阶段细胞均可见。

红系增生活跃且分化成熟较好,以晚幼红细胞增生为主。

纯红细胞再生障碍性贫血( pure red ce ll ap lasia, PRCA )是贫血中较特殊的一种类型,以骨髓红系造血障碍,而粒系、巨核系基本正常为特征 ,该病较少见,约占再生障碍性贫血总数的3% ,纯红再障贫血必须查到找病因,并对因治疗后才能取得好的疗效。

PRCA病因



继发性PRCA中最常见感染病因:微小病毒 B19感染 、EB病毒感染、巨细胞感染、支原体肺炎等其他感染。

PRCA发病机制不清。



肝移植术后出现纯红再障的易发因素

1、移植术后钙调磷酸酶抑制剂的应用;

2、免疫力差导致微小病毒B19的感染;

3、术中失血、术后营养状态差导致贫血未被重视;

4、ABO血型不符合的移植使其存在理论依据可能;该病例主要考虑是移植术后钙调磷酸酶抑制剂的应用和免疫力差导致微小病毒B19的感染导致。

PRCA治疗方案

对症治疗:输注浓缩红细胞

对因治疗:去除病因才能从根本上纠正PRCA

HPV-B19 感染后治疗尚缺乏统一标准:

首选大剂量I静脉免疫球蛋白治疗,0.4g/kg/d,连用5天 ;

转换或降低免疫抑制方案,他克莫司换为环孢素 ;

激素治疗;

93%的患者经大剂量免疫球蛋白治疗有效,但约为1/3患者在3~4月复发。

小结

移植术后HPV B19感染导致PRCA的病例较少,但症状重,尽早明确诊断及治疗,可以缩短病程,改善预后 ,大剂量丙种球蛋白是有效的治疗手段 ,器官移植术后或其他免疫功能低下人群,如果出现不明安全原因的血红蛋白明显下降,应注意排除HPV B19感染 。

-------------------------

专家介绍



臧红:副主任医师;解放军302医院移植内科副主任,医学博士。

专业擅长:长期从事各种慢性肝病的诊治,尤其对终末期肝病、肝衰竭的救治及肝移植患者的管理具有丰富的临床经验。

主要成绩:发表中英文论文40余篇,第一完成人获军队医疗成果三等奖1项,国家实用新型专利1项。

任职:中华医学会肝病学分会自身免疫性肝病协作组委员、 全军传染病专业委员会青年委员、重肝与肝衰竭学组委员、北京亚太肝病诊疗技术联盟北京联盟秘书长。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1998933, encodeId=14a5199893386, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 20 05:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275322, encodeId=644b2e532247, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 04 08:45:51 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275291, encodeId=aea42e529138, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Thu Jan 04 07:31:15 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275271, encodeId=d7e12e52711e, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:32 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275270, encodeId=aafd2e5270c2, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:27 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275246, encodeId=d2282e524679, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jan 04 06:47:17 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275225, encodeId=85c12e52251c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jan 04 05:18:02 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275211, encodeId=abd12e5211ea, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Thu Jan 04 02:23:32 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-03-20 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=1998933, encodeId=14a5199893386, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 20 05:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275322, encodeId=644b2e532247, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 04 08:45:51 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275291, encodeId=aea42e529138, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Thu Jan 04 07:31:15 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275271, encodeId=d7e12e52711e, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:32 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275270, encodeId=aafd2e5270c2, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:27 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275246, encodeId=d2282e524679, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jan 04 06:47:17 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275225, encodeId=85c12e52251c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jan 04 05:18:02 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275211, encodeId=abd12e5211ea, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Thu Jan 04 02:23:32 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 龙胆草

    学习谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1998933, encodeId=14a5199893386, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 20 05:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275322, encodeId=644b2e532247, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 04 08:45:51 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275291, encodeId=aea42e529138, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Thu Jan 04 07:31:15 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275271, encodeId=d7e12e52711e, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:32 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275270, encodeId=aafd2e5270c2, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:27 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275246, encodeId=d2282e524679, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jan 04 06:47:17 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275225, encodeId=85c12e52251c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jan 04 05:18:02 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275211, encodeId=abd12e5211ea, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Thu Jan 04 02:23:32 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 情途末路

    学习了.获益匪浅!感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1998933, encodeId=14a5199893386, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 20 05:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275322, encodeId=644b2e532247, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 04 08:45:51 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275291, encodeId=aea42e529138, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Thu Jan 04 07:31:15 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275271, encodeId=d7e12e52711e, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:32 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275270, encodeId=aafd2e5270c2, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:27 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275246, encodeId=d2282e524679, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jan 04 06:47:17 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275225, encodeId=85c12e52251c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jan 04 05:18:02 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275211, encodeId=abd12e5211ea, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Thu Jan 04 02:23:32 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 榄枷檬

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1998933, encodeId=14a5199893386, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 20 05:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275322, encodeId=644b2e532247, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 04 08:45:51 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275291, encodeId=aea42e529138, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Thu Jan 04 07:31:15 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275271, encodeId=d7e12e52711e, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:32 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275270, encodeId=aafd2e5270c2, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:27 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275246, encodeId=d2282e524679, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jan 04 06:47:17 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275225, encodeId=85c12e52251c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jan 04 05:18:02 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275211, encodeId=abd12e5211ea, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Thu Jan 04 02:23:32 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 榄枷檬

    学习学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1998933, encodeId=14a5199893386, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 20 05:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275322, encodeId=644b2e532247, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 04 08:45:51 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275291, encodeId=aea42e529138, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Thu Jan 04 07:31:15 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275271, encodeId=d7e12e52711e, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:32 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275270, encodeId=aafd2e5270c2, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:27 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275246, encodeId=d2282e524679, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jan 04 06:47:17 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275225, encodeId=85c12e52251c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jan 04 05:18:02 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275211, encodeId=abd12e5211ea, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Thu Jan 04 02:23:32 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 1dd8c52fm63(暂无匿称)

    学习学习.了解了解

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1998933, encodeId=14a5199893386, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 20 05:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275322, encodeId=644b2e532247, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 04 08:45:51 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275291, encodeId=aea42e529138, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Thu Jan 04 07:31:15 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275271, encodeId=d7e12e52711e, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:32 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275270, encodeId=aafd2e5270c2, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:27 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275246, encodeId=d2282e524679, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jan 04 06:47:17 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275225, encodeId=85c12e52251c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jan 04 05:18:02 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275211, encodeId=abd12e5211ea, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Thu Jan 04 02:23:32 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 yjs木玉

    好好好好好好好好

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1998933, encodeId=14a5199893386, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 20 05:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275322, encodeId=644b2e532247, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Jan 04 08:45:51 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275291, encodeId=aea42e529138, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Thu Jan 04 07:31:15 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275271, encodeId=d7e12e52711e, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:32 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275270, encodeId=aafd2e5270c2, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Jan 04 07:20:27 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275246, encodeId=d2282e524679, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jan 04 06:47:17 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275225, encodeId=85c12e52251c, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jan 04 05:18:02 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275211, encodeId=abd12e5211ea, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Thu Jan 04 02:23:32 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 jihuaijun1112

    学习学习学习

    0

相关资讯

郑树森带领团队完成全球罕见超难肝移植手术

2017年9月17日晚,树兰(杭州)医院的手术室灯火通明,这里正在进行着一场别开生面的、手术难度极高的肝移植手术。56岁的患者诸先生(化名)既往因为肺结节病和肝硬化,求医问药20余年,但肝病一直在逐渐进展恶化,最终导致反复的消化道大出血,让他陷入绝境,生命垂危,一次又一次的与死神擦肩而过。肝移植是他最后唯一的选择,他和他的家人找到了肝移植权威专家郑树森院士。但是,要做肝移植,患者的身体似乎难以承受

肝移植术纳入基本医保 浙江试点按绩效支付

从2018年1月1日起,浙江将在全国率先开展肝移植术基本医疗保险按绩效支付试点。肝移植术将按“乙类”项目纳入基本医疗保险支付范围,个人自理比例30%。为减轻肝移植患者医疗费用负担,浙江省人力社保厅近日决定,将从2018年1月1日起开展肝移植术基本医疗保险按绩效支付试点,保障对象为参加基本医疗保险的浙江省户籍患者,或在接受肝移植术前参加浙江省基本医疗保险连续缴费满1年的患者。肝移植术按“乙类”项目纳

Hepatology:HCV阳性肝移植到HCV阴性患者中的预后如何?

根据目前的治疗指导方针,考虑到同种异体移植丙型肝炎病毒(HCV)感染相关的不良移植后结果,HCV阳性的肝脏不会移植到HCV阴性的接受者体内。然而,目前使用直接作用的抗病毒药物(DAAs),肝移植(LT)后的HCV可以被治愈且成功率> 90%。因此,肝移植(LT)候选名单上的HCV阴性患者可能会受益于接受HCV阳性器官并进行抢先治疗。近期,一项发表杂志Hepatology上的研究评估了哪些HC

中科院院士樊嘉:门诊不限号 手术敢闯“禁区”

中国科学院2017年新增院士昨天揭晓,新增院士樊嘉在肝肿瘤领域树起标杆。樊嘉有哪些创新感悟呢?

明年起浙江肝移植费用纳入医保!**可报销70%

浙江省人力资源和社会保障厅近日发布消息,从2018年1月1日起,浙江将在全国率先开展肝移植术基本医疗保险按绩效支付试点。肝移植术将按乙类项目纳入基本医疗保险支付范围,个人自付比例为30%。据介绍,此次肝移植基本医疗保险的保障对象限参加浙江省基本医疗保险的浙江省户籍患者,或在接受肝移植术前参加浙江省基本医疗保险连续缴费满1年的患者。试点医院包括浙江大学医学院附属第一医院、浙江大学医学院附属第二医院、

浙江试点肝移植费用纳入医保

浙江省人力资源和社会保障厅近日发布消息,从2018年1月1日起,浙江将在全国率先开展肝移植术基本医疗保险按绩效支付试点。肝移植术将按乙类项目纳入基本医疗保险支付范围,个人自付比例为30%。